Citizens Business Bank acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 18,750 shares of the biopharmaceutical company's stock, valued at approximately $454,000.
A number of other hedge funds have also recently made changes to their positions in PFE. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. GAMMA Investing LLC raised its stake in Pfizer by 69.0% in the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock valued at $1,600,000 after buying an additional 25,785 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Pfizer by 55.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company's stock valued at $66,039,000 after buying an additional 928,180 shares during the last quarter. Finally, CWA Asset Management Group LLC raised its stake in Pfizer by 4.0% in the first quarter. CWA Asset Management Group LLC now owns 32,184 shares of the biopharmaceutical company's stock valued at $816,000 after buying an additional 1,225 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Stock Up 1.2%
Pfizer stock opened at $24.52 on Friday. The firm has a market cap of $139.38 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 0.80 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.36. The business's 50-day moving average price is $24.89 and its 200 day moving average price is $24.12. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. UBS Group reissued a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.13.
Read Our Latest Research Report on Pfizer
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.